{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:59:15Z","timestamp":1790197155099,"version":"4.1.0"},"reference-count":167,"publisher":"American Society of Clinical Oncology (ASCO)","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Oncol Pract"],"abstract":"<jats:p>\n                    Cholangiocarcinoma (CCA) includes a heterogeneous group of malignancies arising from the biliary epithelium, anatomically classified into intrahepatic, perihilar, and distal disease, with subtype-specific molecular features and treatment implications. Intrahepatic CCA is further subclassified into small- and large-duct variants. Most patients present with advanced, unresectable disease, and 5-year survival rates remain poor. For over a decade, gemcitabine-cisplatin (Gem-Cis) combination chemotherapy was the only established first-line standard of care. More recently, the addition of immune checkpoint inhibitors (IO), durvalumab and pembrolizumab, to Gem-Cis in the TOPAZ-1 and KEYNOTE-966 trials, respectively, improved overall survival, establishing chemoimmunotherapy as the new first-line therapy. Given the high prevalence of actionable alterations in CCA, comprehensive molecular profiling has become indispensable for second-line treatment selection and front-line clinical trial eligibility.\n                    <jats:italic toggle=\"yes\">FGFR2<\/jats:italic>\n                    fusions,\n                    <jats:italic toggle=\"yes\">IDH1<\/jats:italic>\n                    mutations, and\n                    <jats:italic toggle=\"yes\">HER2<\/jats:italic>\n                    amplification are among the most relevant, with several targeted agents now available in the second-line setting. Despite this progress, most patients exhaust treatment options within the first year, highlighting the need for further therapeutic advances. Emerging strategies include novel targeted agents, antibody-drug conjugates, locoregional approaches for liver-limited disease, and circulating tumor DNA monitoring for real-time treatment adaptation. The immunosuppressive tumor microenvironment and the absence of reliable predictive biomarkers for IO response remain key challenges that ongoing research aims to address. This review summarizes current evidence for the management of advanced CCA, focusing on molecular profiling, treatment sequencing, and emerging therapies.\n                  <\/jats:p>","DOI":"10.1200\/op-26-00539","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:59:20Z","timestamp":1790193560000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":0,"title":["Personalized Therapy in Advanced Cholangiocarcinoma: Contemporary Treatment Approaches and Future Directions"],"prefix":"10.1200","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0102-1789","authenticated-orcid":true,"given":"Fen","family":"Saj","sequence":"first","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7203-8011","authenticated-orcid":true,"given":"Camila Braganca","family":"Xavier","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9777-6221","authenticated-orcid":true,"given":"Lipika","family":"Goyal","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, Stanford Cancer Center, Palo Alto, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9158-0941","authenticated-orcid":true,"given":"Milind","family":"Javle","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9281-480X","authenticated-orcid":true,"given":"Shubham","family":"Pant","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-025-01153-w"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v2.i12.419"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/jhbp.154"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyac150"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-025-00599-1"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2026.44.2_suppl.587"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.4091"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30915-X"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00153-7"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.21037\/jgo-2025-411"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100378"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5794"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0908721"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00027-9"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200015"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00727-4"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00770-1"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30010030"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.14.4131"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2011.131"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-022-01824-4"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-014-4247-8"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf352"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2025.0042"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.506"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0078"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2026.05.005"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40487-025-00370-2"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9092854"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.03.007"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-49860-0"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","unstructured":"Mody K Kasi PM Yang J et al: Circulating tumor DNA profiling of advanced biliary tract cancers. JCO Precis Oncol 10.1200\/PO.18.00324","DOI":"10.1200\/PO.18.00324"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.09.150"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1200\/PO-24-00443"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.3109\/1354750X.2014.923048"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjsurg.2008.12.031"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1975.03260040020016"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.01.038"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29913"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-025-17776-x"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1080\/13651820801993540"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(24)00095-5"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2025.05.003"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00486-1"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(24)00119-5"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30109-1"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103488"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206834"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(21)00196-5"},{"key":"e_1_3_4_51_2","article-title":"Erdafitinib in patients with FGFR-altered advanced or metastatic cholangiocarcinoma","author":"Pant S","year":"2025","unstructured":"Pant S, Park JO, Su WC, et al: Erdafitinib in patients with FGFR-altered advanced or metastatic cholangiocarcinoma. Clin Cancer Res, 2025","journal-title":"Clin Cancer Res"},{"key":"e_1_3_4_52_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2026.44.2_suppl.476"},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(25)00230-4"},{"key":"e_1_3_4_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30157-1"},{"key":"e_1_3_4_55_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.3836"},{"key":"e_1_3_4_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00242-5"},{"key":"e_1_3_4_57_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2025.4736"},{"key":"e_1_3_4_58_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02005"},{"key":"e_1_3_4_59_2","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2022-0214"},{"key":"e_1_3_4_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00336-3"},{"key":"e_1_3_4_61_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00606"},{"key":"e_1_3_4_62_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02321-8"},{"key":"e_1_3_4_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30856-3"},{"key":"e_1_3_4_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30691-6"},{"key":"e_1_3_4_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00541-1"},{"key":"e_1_3_4_66_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01931-y"},{"key":"e_1_3_4_67_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-026-01136-z"},{"key":"e_1_3_4_68_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02105"},{"key":"e_1_3_4_69_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.41165"},{"key":"e_1_3_4_70_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.4093"},{"key":"e_1_3_4_71_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-25-1834"},{"key":"e_1_3_4_72_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114199"},{"key":"e_1_3_4_73_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2026.44.2_suppl.546"},{"key":"e_1_3_4_74_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.122"},{"key":"e_1_3_4_75_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31092"},{"key":"e_1_3_4_76_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31410"},{"key":"e_1_3_4_77_2","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2025.2590695"},{"key":"e_1_3_4_78_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1651769"},{"key":"e_1_3_4_79_2","doi-asserted-by":"publisher","unstructured":"Mody K Jain P El-Refai SM et al: Clinical genomic and transcriptomic data profiling of biliary tract cancer reveals subtype-specific immune signatures. JCO Precision Oncol 10.1200\/PO.21.00510","DOI":"10.1200\/PO.21.00510"},{"key":"e_1_3_4_80_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.4_suppl.607"},{"key":"e_1_3_4_81_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.091"},{"key":"e_1_3_4_82_2","doi-asserted-by":"publisher","DOI":"10.1080\/17520363.2024.2385297"},{"key":"e_1_3_4_83_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-021-01583-8"},{"key":"e_1_3_4_84_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.4111"},{"key":"e_1_3_4_85_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-1000"},{"key":"e_1_3_4_86_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-0697"},{"key":"e_1_3_4_87_2","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-0429"},{"key":"e_1_3_4_88_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.4_suppl.TPS600"},{"key":"e_1_3_4_89_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2026.44.16_suppl.4124"},{"key":"e_1_3_4_90_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100469"},{"key":"e_1_3_4_91_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.e16643"},{"key":"e_1_3_4_92_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2025.0242"},{"key":"e_1_3_4_93_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2026.44.2_suppl.567"},{"key":"e_1_3_4_94_2","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyag228"},{"key":"e_1_3_4_95_2","doi-asserted-by":"publisher","DOI":"10.1177\/1073274820983013"},{"key":"e_1_3_4_96_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.9840"},{"key":"e_1_3_4_97_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02903-0"},{"key":"e_1_3_4_98_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00247-3"},{"key":"e_1_3_4_99_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714448"},{"key":"e_1_3_4_100_2","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae011"},{"key":"e_1_3_4_101_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114981"},{"key":"e_1_3_4_102_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-0669"},{"key":"e_1_3_4_103_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.2339"},{"key":"e_1_3_4_104_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.3011"},{"key":"e_1_3_4_105_2","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001006"},{"key":"e_1_3_4_106_2","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf094"},{"key":"e_1_3_4_107_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-25-0762"},{"key":"e_1_3_4_108_2","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2023-0963"},{"key":"e_1_3_4_109_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0415"},{"key":"e_1_3_4_110_2","doi-asserted-by":"publisher","unstructured":"Al Baghdadi T Rothe M Mangat PK et al: Olaparib in patients with solid tumors with BRCA1\/2 alterations: Results from the targeted agent and profiling utilization registry (TAPUR) study. JCO Precis Oncol 10.1200\/PO-25-00649","DOI":"10.1200\/PO-25-00649"},{"key":"e_1_3_4_111_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-01009-1"},{"key":"e_1_3_4_112_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70333-X"},{"key":"e_1_3_4_113_2","doi-asserted-by":"publisher","DOI":"10.21037\/hbsn-20-338"},{"key":"e_1_3_4_114_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-3548"},{"key":"e_1_3_4_115_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0044"},{"key":"e_1_3_4_116_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2026.44.16_suppl.e16004"},{"key":"e_1_3_4_117_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-026-01457-3"},{"key":"e_1_3_4_118_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-26-0428"},{"key":"e_1_3_4_119_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.70227"},{"key":"e_1_3_4_120_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.446"},{"key":"e_1_3_4_121_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34394"},{"key":"e_1_3_4_122_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4593"},{"key":"e_1_3_4_123_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.4_suppl.387"},{"key":"e_1_3_4_124_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35352"},{"key":"e_1_3_4_125_2","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000965"},{"key":"e_1_3_4_126_2","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.10641"},{"key":"e_1_3_4_127_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2020.100614"},{"key":"e_1_3_4_128_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(18)30045-1"},{"key":"e_1_3_4_129_2","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.16906"},{"key":"e_1_3_4_130_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2012.04.008"},{"key":"e_1_3_4_131_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2015.02.024"},{"key":"e_1_3_4_132_2","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-013-3035-1"},{"key":"e_1_3_4_133_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.3778"},{"key":"e_1_3_4_134_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2009.11.004"},{"key":"e_1_3_4_135_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.4006"},{"key":"e_1_3_4_136_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-25-3368"},{"key":"e_1_3_4_137_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.191"},{"key":"e_1_3_4_138_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.3702"},{"key":"e_1_3_4_139_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmp.2019.09.236"},{"key":"e_1_3_4_140_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25625"},{"key":"e_1_3_4_141_2","first-page":"437","article-title":"Treatment of unresectable cholangiocarcinoma: Conventional transarterial chemoembolization compared with drug eluting bead-transarterial chemoembolization and systemic chemotherapy","volume":"24","author":"Kuhlmann JB","year":"2012","unstructured":"Kuhlmann JB, Euringer W, Spangenberg HC, et al: Treatment of unresectable cholangiocarcinoma: Conventional transarterial chemoembolization compared with drug eluting bead-transarterial chemoembolization and systemic chemotherapy. Eur J Gastroenterol Hepatol 24:437-443, 2012","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"e_1_3_4_142_2","doi-asserted-by":"publisher","DOI":"10.1080\/02656736.2022.2112309"},{"key":"e_1_3_4_143_2","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.233051"},{"key":"e_1_3_4_144_2","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000006720"},{"key":"e_1_3_4_145_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.3718"},{"key":"e_1_3_4_146_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00923"},{"key":"e_1_3_4_147_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29824"},{"key":"e_1_3_4_148_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP.23.00374"},{"key":"e_1_3_4_149_2","doi-asserted-by":"publisher","DOI":"10.5009\/gnl18339"},{"key":"e_1_3_4_150_2","doi-asserted-by":"publisher","DOI":"10.4251\/wjgo.v8.i6.498"},{"key":"e_1_3_4_151_2","doi-asserted-by":"publisher","DOI":"10.1055\/a-0990-9114"},{"key":"e_1_3_4_152_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41395-018-0122-8"},{"key":"e_1_3_4_153_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v23.i7.1278"},{"key":"e_1_3_4_154_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.gie.2017.10.029"},{"key":"e_1_3_4_155_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26359"},{"key":"e_1_3_4_156_2","doi-asserted-by":"publisher","DOI":"10.1002\/jso.26713"},{"key":"e_1_3_4_157_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0337"},{"key":"e_1_3_4_158_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.1474"},{"key":"e_1_3_4_159_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.suc.2024.03.008"},{"key":"e_1_3_4_160_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-026-01602-6"},{"key":"e_1_3_4_161_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105049"},{"key":"e_1_3_4_162_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2026.44.2_suppl.597"},{"key":"e_1_3_4_163_2","doi-asserted-by":"publisher","unstructured":"Peshin S Saj F Kasi PM et al: ErbB receptor feedback inhibitor 1 mutation in biliary tract cancers: Turning resistance into response JCO Precision Oncology 10.1200\/PO-25-00673","DOI":"10.1200\/PO-25-00673"},{"key":"e_1_3_4_164_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1251102"},{"key":"e_1_3_4_165_2","doi-asserted-by":"publisher","DOI":"10.1093\/jimmun\/vkaf242"},{"key":"e_1_3_4_166_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102349"},{"key":"e_1_3_4_167_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2025.118806"},{"key":"e_1_3_4_168_2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-012107"}],"container-title":["JCO Oncology Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/OP-26-00539","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:59:22Z","timestamp":1790193562000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/OP-26-00539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":167,"alternative-id":["10.1200\/OP-26-00539"],"URL":"https:\/\/doi.org\/10.1200\/op-26-00539","relation":{},"ISSN":["2688-1527","2688-1535"],"issn-type":[{"value":"2688-1527","type":"print"},{"value":"2688-1535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]},"assertion":[{"value":"2026-04-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-03","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"OP-26-00539"}}